Trial Profile

Pivmecillinam as oral step-down treatment for Escherichia coli febrile urinary tract infection versus standard of care; a randomized controlled non-inferiority multicenter trial - PIVOT

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pivmecillinam (Primary) ; Amikacin sulfate; Amoxicillin; Amoxicillin/clavulanic acid; Ampicillin; Aztreonam; Betamethasone valerate; Bromhexine/sulfamethoxazole/trimethoprim; Cefotaxime; Cefotaxime/lidocaine; Ceftriaxone; Cefuroxime axetil; Cilastatin; Ciprofloxacin; Ertapenem; Fosfomycin; Gentamicin; Imipenem; Imipenem/cilastatin; Lidocaine; Linezolid; Piperacillin/tazobactam
Indications Escherichia coli infections; Fever; Urinary tract infections
Focus Therapeutic Use
Acronyms PIVOT

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com